tetano
Editor, Senior Moderator
Arch Virol
. 2023 Jun 28;168(7):194.
doi: 10.1007/s00705-023-05825-3. Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients
Mohammad Fayyad-Kazan[SUP] #[/SUP][SUP] 1 [/SUP], Rawan Makki[SUP] #[/SUP][SUP] 2 [/SUP], Mahmoud El Homsi[SUP] 2 [/SUP], Ahmad Samadi[SUP] 3 [/SUP], Hilal Chaaban[SUP] 3 [/SUP], Rania El Majzoub[SUP] 2 4 [/SUP], Eva Hamade[SUP] 2 [/SUP], Hussein Fayyad-Kazan[SUP] #[/SUP][SUP] 2 [/SUP], Bassam Badran[SUP] #[/SUP][SUP] 5 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19), a serious infectious disease caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a major global health crisis. Although no specific antiviral drugs have been proven to be fully effective against COVID-19, remdesivir (GS-5734), a nucleoside analogue prodrug, has shown beneficial effects when used to treat severe hospitalized COVID-19 cases. The molecular mechanism underlying this beneficial therapeutic effect is still vaguely understood. In this study, we assessed the effect of remdesivir treatment on the pattern of circulating miRNAs in the plasma of COVID-19 patients, which was analyzed using MiRCURY LNA miRNA miRNome qPCR Panels and confirmed by quantitative real-time RT-PCR (qRT-PCR). The results revealed that remdesivir treatment can restore the levels of miRNAs that are upregulated in COVID-19 patients to the range observed in healthy subjects. Bioinformatics analysis revealed that these miRNAs are involved in diverse biological processes, including the transforming growth factor beta (TGF-β), hippo, P53, mucin-type O-glycan biosynthesis, and glycosaminoglycan biosynthesis signaling pathways. On the other hand, three miRNAs (hsa-miR-7-5p, hsa-miR-10b-5p, and hsa-miR-130b-3p) were found to be upregulated in patients receiving remdesivir treatment and in patients who experienced natural remission. These upregulated miRNAs could serve as biomarkers of COVID-19 remission. This study highlights that the therapeutic potential of remdesivir involves alteration of certain miRNA-regulated biological processes. Targeting of these miRNAs should therefore be considered for future COVID-19 treatment strategies.
. 2023 Jun 28;168(7):194.
doi: 10.1007/s00705-023-05825-3. Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients
Mohammad Fayyad-Kazan[SUP] #[/SUP][SUP] 1 [/SUP], Rawan Makki[SUP] #[/SUP][SUP] 2 [/SUP], Mahmoud El Homsi[SUP] 2 [/SUP], Ahmad Samadi[SUP] 3 [/SUP], Hilal Chaaban[SUP] 3 [/SUP], Rania El Majzoub[SUP] 2 4 [/SUP], Eva Hamade[SUP] 2 [/SUP], Hussein Fayyad-Kazan[SUP] #[/SUP][SUP] 2 [/SUP], Bassam Badran[SUP] #[/SUP][SUP] 5 [/SUP]
Affiliations
- PMID: 37380930
- DOI: 10.1007/s00705-023-05825-3
Coronavirus disease 2019 (COVID-19), a serious infectious disease caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a major global health crisis. Although no specific antiviral drugs have been proven to be fully effective against COVID-19, remdesivir (GS-5734), a nucleoside analogue prodrug, has shown beneficial effects when used to treat severe hospitalized COVID-19 cases. The molecular mechanism underlying this beneficial therapeutic effect is still vaguely understood. In this study, we assessed the effect of remdesivir treatment on the pattern of circulating miRNAs in the plasma of COVID-19 patients, which was analyzed using MiRCURY LNA miRNA miRNome qPCR Panels and confirmed by quantitative real-time RT-PCR (qRT-PCR). The results revealed that remdesivir treatment can restore the levels of miRNAs that are upregulated in COVID-19 patients to the range observed in healthy subjects. Bioinformatics analysis revealed that these miRNAs are involved in diverse biological processes, including the transforming growth factor beta (TGF-β), hippo, P53, mucin-type O-glycan biosynthesis, and glycosaminoglycan biosynthesis signaling pathways. On the other hand, three miRNAs (hsa-miR-7-5p, hsa-miR-10b-5p, and hsa-miR-130b-3p) were found to be upregulated in patients receiving remdesivir treatment and in patients who experienced natural remission. These upregulated miRNAs could serve as biomarkers of COVID-19 remission. This study highlights that the therapeutic potential of remdesivir involves alteration of certain miRNA-regulated biological processes. Targeting of these miRNAs should therefore be considered for future COVID-19 treatment strategies.